Mitsubishi UFJ Asset Management Co. Ltd. Has $79.79 Million Stake in Kenvue Inc. $KVUE

Key Points

• Mitsubishi UFJ Asset Management increased its Q4 stake in Kenvue by 3.9%, holding 4,606,499 shares (≈0.24% of the company) worth about $79.79 million.
• Kenvue beat quarterly estimates (EPS $0.32 vs $0.27; revenue $3.91B vs $3.84B) and announced a $0.2075 quarterly dividend (annualized yield ~4.7%) despite a high payout ratio (~107.8%); analysts' consensus rating is Hold with a $19.33 price target.

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 3.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,606,499 shares of the company's stock after buying an additional 174,559 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.24% of Kenvue worth $79,785,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in KVUE. Van ECK Associates Corp grew its position in Kenvue by 101.3% during the third quarter. Van ECK Associates Corp now owns 18,361,581 shares of the company's stock worth $298,008,000 after buying an additional 9,240,434 shares in the last quarter. American Century Companies Inc. grew its position in Kenvue by 22.4% during the third quarter. American Century Companies Inc. now owns 37,046,660 shares of the company's stock worth $601,267,000 after buying an additional 6,781,640 shares in the last quarter. Mondrian Investment Partners LTD acquired a new stake in Kenvue during the third quarter worth approximately $79,269,000. Alliancebernstein L.P. grew its position in Kenvue by 115.9% during the second quarter. Alliancebernstein L.P. now owns 6,438,473 shares of the company's stock worth $134,757,000 after buying an additional 3,456,204 shares in the last quarter. Finally, Amundi grew its position in Kenvue by 21.6% during the third quarter. Amundi now owns 17,645,761 shares of the company's stock worth $277,012,000 after buying an additional 3,135,871 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Trading Up 0.3%

Shares of KVUE stock opened at $17.74 on Friday. The stock's fifty day moving average price is $17.65 and its two-hundred day moving average price is $17.24. The company has a market cap of $34.06 billion, a PE ratio of 23.04, a P/E/G ratio of 4.01 and a beta of 0.55. Kenvue Inc. has a fifty-two week low of $14.02 and a fifty-two week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.96.

Kenvue (NYSE:KVUE - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion for the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a return on equity of 19.72% and a net margin of 9.72%.The company's revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.24 EPS. Equities analysts predict that Kenvue Inc. will post 1.1 EPS for the current fiscal year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be issued a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend is Wednesday, May 13th. Kenvue's dividend payout ratio (DPR) is currently 107.79%.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KVUE. Jefferies Financial Group downgraded Kenvue from a "buy" rating to a "hold" rating and reduced their price target for the stock from $23.00 to $18.00 in a research report on Friday, January 30th. Canaccord Genuity Group increased their price target on Kenvue from $17.00 to $18.00 and gave the stock a "hold" rating in a research report on Wednesday, February 18th. Citigroup reduced their price target on Kenvue from $20.00 to $19.00 and set a "neutral" rating on the stock in a research report on Wednesday, April 15th. Barclays reduced their price target on Kenvue from $19.00 to $18.00 and set an "equal weight" rating on the stock in a research report on Tuesday, April 14th. Finally, Argus raised Kenvue to a "hold" rating in a report on Friday, March 6th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the stock. According to MarketBeat, Kenvue has a consensus rating of "Hold" and a consensus price target of $19.33.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.